Irvine-based startup CardiAQ Valve Technologies Inc. said today that it has received $37.3 million in a second round of financing.
CardiAQ is developing a replacement mitral heart valve inserted via a catheter.
The company said it will use the money to “further validate” its technology and expects the funding to carry it through overseas clinical trials.
OrbiMed Advisors LLC, a New York-based venture capital firm, led CardiAQ’s investment. Other investors include Menlo Park-based Versant Ventures Inc., which has an office in Newport Beach.
